Overview

* Progyny Q3 2025 revenue grows 9.3%, beating analyst expectations

* Adjusted EBITDA for Q3 2025 beats analyst estimates, reflecting strong operational performance

* Company announces $200 mln share repurchase program, indicating confidence in financial position

Outlook

* Progyny ( PGNY ) raises full-year 2025 revenue guidance to $1.263 bln-$1.278 bln

* Company expects 4Q 2025 revenue between $292.7 mln and $307.7 mln

Result Drivers

* MEMBER ENGAGEMENT - Strong member engagement exceeded expectations, driving revenue growth, per CEO Pete Anevski

* NEW CLIENTS - Over 80 new clients and 900,000 new lives added, with near 100% retention, boosting growth

* PROGRAM SUCCESS - New programs like pregnancy-postpartum and menopause resonate in the market, contributing to growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $313.35 $299.26

Revenue mln mln (10

Analysts

)

Q3 EPS $0.15

Q3 Net $13.86

Income mln

Q3 Beat $54.97 $46.70

Adjusted mln mln (10

EBITDA Analysts

)

Q3 Gross $72.84

Profit mln

Q3 $23.96

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the managed healthcare peer group is "buy"

* Wall Street's median 12-month price target for Progyny Inc ( PGNY ) is $30.00, about 37.1% above its November 5 closing price of $18.88

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)